These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19800951)

  • 1. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
    Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
    Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
    Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
    Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.
    Fischetti C; Camarda V; Rizzi A; Pelà M; Trapella C; Guerrini R; McDonald J; Lambert DG; Salvadori S; Regoli D; Calo' G
    Eur J Pharmacol; 2009 Jul; 614(1-3):50-7. PubMed ID: 19445927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
    Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro binding and functional studies of Ac-RYYRIK-ol and its derivatives, novel partial agonists of the nociceptin/orphanin F/Q receptor.
    Gunduz O; Sipos F; Spagnolo B; Kocsis L; Magyar A; Orosz G; Borsodi A; Calò G; Benyhe S
    Neurosignals; 2006-2007; 15(2):91-101. PubMed ID: 16874009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.
    Ibba M; Kitayama M; McDonald J; Calo G; Guerrini R; Farkas J; Toth G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):553-61. PubMed ID: 18807245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.
    Molinari S; Camarda V; Rizzi A; Marzola G; Salvadori S; Marzola E; Molinari P; McDonald J; Ko MC; Lambert DG; Calo' G; Guerrini R
    Br J Pharmacol; 2013 Jan; 168(1):151-62. PubMed ID: 22827708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol.
    Bojnik E; Farkas J; Magyar A; Tömböly C; Güçlü U; Gündüz O; Borsodi A; Corbani M; Benyhe S
    Neurochem Int; 2009 Dec; 55(7):458-66. PubMed ID: 19414055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
    Carrà G; Rizzi A; Guerrini R; Barnes TA; McDonald J; Hebbes CP; Mela F; Kenigs VA; Marzola G; Rizzi D; Gavioli E; Zucchini S; Regoli D; Morari M; Salvadori S; Rowbotham DJ; Lambert DG; Kapusta DR; Calo' G
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1114-23. PubMed ID: 15509719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
    Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
    Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
    Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties.
    Berger H; Bigoni R; Albrecht E; Richter RM; Krause E; Bienert M; Calo' G
    Peptides; 2000 Jul; 21(7):1131-9. PubMed ID: 10998548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes.
    Johnson EE; McDonald J; Nicol B; Guerrini R; Lambert DG
    Brain Res; 2004 Apr; 1003(1-2):18-25. PubMed ID: 15019559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
    Fischetti C; Rizzi A; Gavioli EC; Marzola G; Trapella C; Guerrini R; Petersen JS; Calo G
    Peptides; 2009 Feb; 30(2):248-55. PubMed ID: 18992780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
    Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
    Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides.
    Erdei AI; Borbély A; Magyar A; Szűcs E; Ötvös F; Gombos D; Al-Khrasani M; Stefanucci A; Dimmito MP; Luisi G; Mollica A; Benyhe S
    Peptides; 2019 Feb; 112():106-113. PubMed ID: 30513351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
    McDonald J; Calo G; Guerrini R; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):183-7. PubMed ID: 12595960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity studies on high affinity NOP-active hexapeptides.
    Judd AK; Tuttle DJ; Jones RW; Sanchez A; Polgar W; Berzetei-Gurske I; Toll L
    J Pept Res; 2004 Sep; 64(3):87-94. PubMed ID: 15317498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
    McDonald J; Barnes TA; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
    Eur J Pharmacol; 2002 May; 443(1-3):7-12. PubMed ID: 12044785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.